Growth and Margin Analysis of Cara Therapeutics Inc. (CARA)’s Recent Quarter Sales

Cara Therapeutics Inc. [CARA] stock is trading at $1.88, down -19.66%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The CARA shares have gain 2.73% over the last week, with a monthly amount drifted -37.54%, and not seem to be holding up well over a long-time horizon.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


On 5, September 2023, Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference. In a post published today on Yahoo Finance, Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 9:00 a.m. EDT in New York, NY.

From an analyst’s perspective:

Cara Therapeutics Inc. [NASDAQ: CARA] stock has seen the most recent analyst activity on March 08, 2023, when BofA Securities downgraded its rating to a Underperform and also revised its price target to $6 from $13.

Cara Therapeutics Inc. [CARA] stock has fluctuated between $1.70 and $12.81 over the past year. Currently, Wall Street analysts expect the stock to reach $15.50 within the next 12 months. Cara Therapeutics Inc. [NASDAQ: CARA] shares were valued at $1.88 at the most recent close of the market. An investor can expect a potential return of 724.47% based on the average CARA price forecast.

Analyzing the CARA fundamentals

Cara Therapeutics Inc. [NASDAQ:CARA] reported sales of 6.93 billion for the most recent quarter, which represents a drop of -70.00%. A company’s income per employee is -$806,358 while it generates $394,972 in revenue per employee. Gross Margin for this corporation currently stands at +82.05% with Operating Margin at -209.08%, Pretax Margin comes in at -204.16%, and Net Margin reading is -204.16%. To continue investigating profitability, this company’s Return on Assets is posted at -39.82, Equity is -44.25, Total Capital is -44.67, and Invested Capital is -44.03. An extended look at the Principal structure reveals enduring liabilities to the total capital of 1.19 and enduring liabilities to assets of 1.05.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.74 points at the first support level, and at 1.59 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.17, and for the 2nd resistance point, it is at 2.45.

Cara Therapeutics Inc. [CARA] reported earnings per share of -$0.58 for its fiscal quarter that ended on 6/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.54/share, meaning a difference of -$0.04 and a surprise factor of -7.40%. By comparison, the stated earnings for the previous quarter ended on 3/30/2023 were -$0.49 per share as compared to estimates of -$0.52 per share, a difference of $0.03 representing a surprise of 5.80%.

Ratios To Look Out For

For context, Cara Therapeutics Inc.’s Current Ratio is 4.90. As well, the Quick Ratio is 7.10, while the Cash Ratio is 6.22. Considering the valuation of this stock, the price to sales ratio is 13.76, the price to book ratio is 3.64.

Transactions by insiders

Insider trading has also been a hot topic recently, with 0 insiders purchasing 0 shares and 4 selling 12,506 shares in the past 3 months. Recent insider trading involved Posner Christopher, President and CEO, that happened on Aug 03 when 4307.0 shares were sold. Chief Scientific Off,SVP-R&D, Menzaghi Frederique Ph.D. completed a deal on Jun 23 to sell 2993.0 shares. Meanwhile, Chief Medical Officer Goncalves Joana sold 2723.0 shares on Jun 23.